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Abstract
Heart failure is a clinical syndrome that can result from any structural or functional cardiac disorder that impairs the 
performance of the ventricle: either to eject blood (systolic dysfunction) [or reduced ejection function] or to fill with blood 
(preserved ejection fraction or diastolic heart failure).
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What is new?
About half of all clinical heart failure patients have preserved 
ejection fraction and this condition seems to be increasing 
in prevalence, especially with increasing age. The most 
effective therapy for this form of heart failure is currently 
unknown.
Comorbidities have a large influence on worse outcome 
in heart failure. Systemic hypertension, ischaemia of the 
ventricle, diabetes mellitus, chronic obstructive pulmonary 
disease, sleep apnoea, depression, anaemia and chronic 
renal disease add considerable complexities to diagnosis 
and management of heart failure.
Biochemical testing for heart failure
Measurement in plasma of brain natriuretic peptide or its 
precursor, N terminal proBNP (NT-proBNP) has aided in the 
diagnosis of heart failure. An elevated NT-proBNP is caused 
by stretching of cardiac myocytes and therefore the test 
cannot distinguish between left ventricular failure or right 
ventricular failure from other causes. A low BNP (or NT-
proBNP) has a high negative predictive value, making it a 
useful rule-out test.
Stages of heart failure
There are four recognisable stages in the progression of 
heart failure.
Stage A: There are no symptoms or signs of heart failure. 
The heart has a normal structure and function, 
but the patient has risk factors for heart failure: 
hypertension, elevated cholesterol, diabetes, 
alcohol abuse, cardiotoxic drugs  
(e.g. chemotherapeutic drugs, cocaine, etc).
Stage B: There are no symptoms or signs but the heart of 
the patient has a structural abnormality (e.g. left 
ventricular hypertrophy, myocardial infarction, 
heart murmur, LV dilatation) or is functionally 
abnormal e.g. reduced ejection fraction, and 
diastolic dysfunction.
Stage C: There are now symptoms and signs of heart 
failure.
Stage D: These patients have progressed and still have 
marked/resistant symptoms despite maximal 
medical therapy.
Therapy for heart failure (What works?)
Physical activity is now recommended for all heart failure 
patients, except for those who are acutely decompensated.
Prevention of heart failure is possible through adequate 
blood pressure control in hypertensives, control of 
ischaemic heart disease occurrence and diabetes mellitus 
[Stage A]. Preventative treatment with an angiotensin-
converting enzyme inhibitor (ACE-I) or angiotensin-receptor 
blocker (ARB) are given to individuals with high risk but 
normal ejection fraction (HOPE study; ONTARGET) or those 
with asymptomatic left ventricular dysfunction [Stage B]. 
Treatment post myocardial infarction with a beta-blocker 
[Stage B] can also slow progression of heart failure. For 
Stage C heart failure (symptoms and signs of heart failure), 
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neuro-hormonal inhibitions for patients with reduced 
ejection fraction has mortality benefits. ACE-inhibitors, 
ARBs, beta-blockers (bisoprolol, metoprolol), alpha-beta 
blockers (carvedilol) and aldosterone antagonists all are 
evidence-based therapies for mortality reduction. Cardiac 
resynchronisation therapy for heart failure with biventricular 
pacemakers with or without intracardiac defibrillators are 
recent additions to mortality reduction therapy. Isobide 
dinitrate plus hydralazime therapy have mortality benefits 
especially in African patients, but can be tried in others 
as well.
What does not reduce mortality? (What 
does not work?)
Statins given purely for heart failure do not reduce mortality. 
Digoxin, once the standard treatment, has not reduced 
mortality compared to placebo, in patients with low ejection 
fraction and in patients with normal ejection fraction. 
Digoxin is used to control atrial fibrillation should it occur 
in heart failure.
Calcium channel blockers also have no mortality benefit. 
Inotropic therapy is associated with increased mortality.
What is the problem with treatment?
The majority of the randomised clinical trials in heart failure 
were done on patients with reduced ejection fraction. These 
patients have improved mortality on standard anti-neuro-
hormonal therapy.
However, the therapy of heart failure patients with preserved 
ejection fraction has very little evidence. The few trials done 
in this condition have not shown the same mortality benefit. 
Much work needs to be done for patients with heart failure 
and preserved ejection fractions (almost half of all heart 
failure patients).
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